|

Visugromab RDE (recommended dose for expansion) Clinical Trials

2 actively recruiting trials across 2 locations

No change since June 2026

Also known as: CTL-002

Pipeline

Phase 2: 2

Top Sponsors

  • CatalYm GmbH2

Indications

  • Cancer2
  • Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound1
  • Child-Pugh A Hepatocellular Carcinoma1
  • Unresectable or Metastatic Hepatocellular Carcinoma1
  • Liver Disease1

Birmingham, Alabama1 trial

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

University of Alabama at Birmingham (O'Neal Comprehensive Cancer Center)

Phase 2

Los Angeles, California1 trial

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

USC Norris Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.